FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:1645-1649 June 9, 1994 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

In tumor-induced osteomalacia, a rare syndrome characterized by hypophosphatemia, hyperphosphaturia, low plasma 1,25-dihydroxyvitamin D concentrations, and osteomalacia,^1,2,3,4,5 all biochemical and pathological abnormalities disappear when the tumor is removed. Tumors associated with this syndrome are thought to secrete a substance that inhibits the renal tubular reabsorption of phosphate,^1,2,3,4,5 but whether this factor interacts directly with renal tubular cells is not known. We investigated the ability of medium in which sclerosing hemangioma cells from a patient with oncogenic osteomalacia were cultured to alter sodium-dependent phosphate transport in opossum-kidney epithelial cells. We found that the medium inhibited phosphate transport, without increasing cellular concentrations . . . [Full Text of this Article]

Case Report

Methods

Cell Culture

Measurement of Sodium-Dependent Phosphate, Alanine, and Glucose Cotransport

Treatment of Medium Obtained from Tumor-Cell Cultures

Assays

Tumor Implantation into Nude Mice

Statistical Analysis

Results

Discussion

Source Information

From the Nephrology Research Unit (Q.C., R.K.), the Neuroimmunology Research Laboratory (V.A.L.), the Section of Biostatistics (A.R.Z.), and the Departments of Medicine (S.F.H., R.K.), Neurology and Immunology (V.A.L.), and Laboratory Medicine and Pathology (P.C.K., G.G.K.), Mayo Clinic, Rochester, Minn.

Address reprint requests to Dr. Kumar at the Mayo Clinic, 200 First St., SW, 911A Guggenheim Bldg., Rochester, MN 55905.

References

Related Letters:

Oncogenic Osteomalacia
Cotton G. E., Kumar R., Hodgson S. F.
Extract | Full Text  
N Engl J Med 1994; 331:1023, Oct 13, 1994. Correspondence

Computer-Based Diagnostic Systems
Lehmann E. D., Yolton R. L., Berner E. S., Webster G. D., Shugerman A. A.
Extract | Full Text  
N Engl J Med 1994; 331:1023-1024, Oct 13, 1994. Correspondence

This article has been cited by other articles:

• Khosravi, A., Cutler, C. M., Kelly, M. H., Chang, R., Royal, R. E., Sherry, R. M., Wodajo, F. M., Fedarko, N. S., Collins, M. T. (2007). Determination of the Elimination Half-Life of Fibroblast Growth Factor-23. J. Clin. Endocrinol. Metab. 92: 2374-2377 [Abstract] [Full Text]  
• White, K. E., Larsson, T. E., Econs, M. J. (2006). The Roles of Specific Genes Implicated as Circulating Factors Involved in Normal and Disordered Phosphate Homeostasis: Frizzled Related Protein-4, Matrix Extracellular Phosphoglycoprotein, and Fibroblast Growth Factor 23. Endocr. Rev. 27: 221-241 [Abstract] [Full Text]  
• Berndt, T. J., Schiavi, S., Kumar, R. (2005). "Phosphatonins" and the regulation of phosphorus homeostasis. Am. J. Physiol. Renal Physiol. 289: F1170-F1182 [Abstract] [Full Text]  
• Jan de Beur, S. M. (2005). Tumor-Induced Osteomalacia. JAMA 294: 1260-1267 [Abstract] [Full Text]  
• Imel, E. A., Econs, M. J. (2005). Fibroblast Growth Factor 23: Roles in Health and Disease. J. Am. Soc. Nephrol. 16: 2565-2575 [Full Text]  
• Yamashita, H., Yamazaki, Y., Hasegawa, H., Yamashita, T., Fukumoto, S., Shigematsu, T., Kazama, J. J., Fukagawa, M., Noguchi, S. (2005). Fibroblast Growth Factor-23 in Patients with Graves' Disease before and after Antithyroid Therapy: Its Important Role in Serum Phosphate Regulation. J. Clin. Endocrinol. Metab. 90: 4211-4215 [Abstract] [Full Text]  
• Berndt, T., Kumar, R. (2005). The Phosphatonins and the Regulation of Phosphorus Homeostasis. IBMS BoneKEy 2: 5-16 [Full Text]  
• Bresler, D., Bruder, J., Mohnike, K., Fraser, W. D, Rowe, P. S N (2004). Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J Endocrinol 183: R1-R9 [Abstract] [Full Text]  
• Rowe, P. S.N. (2004). THE WRICKKENED PATHWAYS OF FGF23, MEPE AND PHEX. Crit. Rev. Oral Biol. Med. 15: 264-281 [Abstract] [Full Text]  
• Nelson, A. E., Bligh, R. C., Mirams, M., Gill, A., Au, A., Clarkson, A., Juppner, H., Ruff, S., Stalley, P., Scolyer, R. A., Robinson, B. G., Mason, R. S., Bligh, P. C. (2003). Fibroblast Growth Factor 23: A New Clinical Marker for Oncogenic Osteomalacia. J. Clin. Endocrinol. Metab. 88: 4088-4094 [Abstract] [Full Text]  
• Azam, N., Zhang, M. Y. H., Wang, X., Tenenhouse, H. S., Portale, A. A. (2003). Disordered Regulation of Renal 25-Hydroxyvitamin D-1{alpha}-Hydroxylase Gene Expression by Phosphorus in X-Linked Hypophosphatemic (Hyp) Mice. Endocrinology 144: 3463-3468 [Abstract] [Full Text]  
• Jan De Beur, S. M., Levine, M. A. (2002). Molecular Pathogenesis of Hypophosphatemic Rickets. J. Clin. Endocrinol. Metab. 87: 2467-2473 [Full Text]  
• Seufert, J., Ebert, K., Muller, J., Eulert, J., Hendrich, C., Werner, E., Schutze, N., Schulz, G., Kenn, W., Richtmann, H., Palitzsch, K.-D., Jakob, F. (2001). Octreotide Therapy for Tumor-Induced Osteomalacia. NEJM 345: 1883-1888 [Full Text]  
• Einhorn, T. A., Nielsen, G. P. (2001). Case 1-2001- A 26-Year-Old Man with a Mass in the Knee. NEJM 344: 124-131 [Full Text]  
• Williams, C P, Child, D F, Hudson, P R, Davies, G K, Davies, M G, John, R, Anandaram, P S, De Bolla, A R (2001). Why oral calcium supplements may reduce renal stone disease: report of a clinical pilot study. J. Clin. Pathol. 54: 54-62 [Abstract] [Full Text]  
• Clunie, G. P. R., Fox, P. E., Stamp, T. C. B. (2000). Four cases of acquired hypophosphataemic ('oncogenic') osteomalacia. Problems of diagnosis, treatment and long-term management. Rheumatology (Oxford) 39: 1415-1421 [Full Text]  
• Murer, H., Hernando, N., Forster, I., Biber, J. (2000). Proximal Tubular Phosphate Reabsorption: Molecular Mechanisms. Physiol. Rev. 80: 1373-1409 [Abstract] [Full Text]  
• ROWE, P S N (2000). The molecular background to hypophosphataemic rickets. Arch. Dis. Child. 83: 192-194 [Full Text]  
• Roig-Vilaseca, D., Moragues-Pastor, C., Nolla-Sole, J. M., Roig-Escofet, D. (2000). Reflex sympathetic dystrophy in hypophosphataemic osteomalacia with femoral neck fracture: a case report. Rheumatology (Oxford) 39: 439-441 [Abstract] [Full Text]  
• Yeung, S. J., McCutcheon, I. E., Schultz, P., Gagel, R. F. (2000). Use of Long-Term Intravenous Phosphate Infusion in the Palliative Treatment of Tumor-Induced Osteomalacia. J. Clin. Endocrinol. Metab. 85: 549-555 [Abstract] [Full Text]  
• Prehn, J. L., Landers, C. J., Targan, S. R. (1999). A Soluble Factor Produced by Lamina Propria Mononuclear Cells Is Required for TNF-{alpha} Enhancement of IFN-{gamma} Production by T Cells. J. Immunol. 163: 4277-4283 [Abstract] [Full Text]  
• Scheinman, S. J., Guay-Woodford, L. M., Thakker, R. V., Warnock, D. G. (1999). Genetic Disorders of Renal Electrolyte Transport. NEJM 340: 1177-1187 [Full Text]  
• Dixon, P. H., Christie, P. T., Wooding, C., Trump, D., Grieff, M., Holm, I., Gertner, J. M., Schmidtke, J., Shah, B., Shaw, N., Smith, C., Tau, C., Schlessinger, D., Whyte, M. P., Thakker, R. V. (1998). Mutational Analysis of PHEX Gene in X-Linked Hypophosphatemia. J. Clin. Endocrinol. Metab. 83: 3615-3623 [Abstract] [Full Text]  
• Lipman, M. L., Panda, D., Bennett, H. P. J., Henderson, J. E., Shane, E., Shen, Y., Goltzman, D., Karaplis, A. C. (1998). Cloning of Human PEX cDNA. EXPRESSION, SUBCELLULAR LOCALIZATION, AND ENDOPEPTIDASE ACTIVITY. J. Biol. Chem. 273: 13729-13737 [Abstract] [Full Text]  
• Guise, T. A., Mundy, G. R. (1998). Cancer and Bone. Endocr. Rev. 19: 18-54 [Abstract] [Full Text]  
• Econs, M. J., Francis, F. (1997). Positional cloning of the PEX gene: new insights into the pathophysiology of X-linked hypophosphatemic rickets. Am. J. Physiol. Renal Physiol. 273: F489-F498 [Abstract] [Full Text]  
• Cotton, G. E., Kumar, R., Hodgson, S. F. (1994). Oncogenic Osteomalacia. NEJM 331: 1023-1023 [Full Text]  
• Econs, M. J., Drezner, M. K. (1994). Tumor-Induced Osteomalacia -- Unveiling a New Hormone. NEJM 330: 1679-1681 [Full Text]  
• Shimada, T., Mizutani, S., Muto, T., Yoneya, T., Hino, R., Takeda, S., Takeuchi, Y., Fujita, T., Fukumoto, S., Yamashita, T. (2001). Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. USA 98: 6500-6505 [Abstract] [Full Text]